https://theracryf.com/post_type_resource/investormeet-presentation/ 2024-10-21T13:19:46+00:00 https://theracryf.com/post_type_resource/2021-placing-and-open-offer-shareholder-circular/ 2024-10-22T10:48:31+00:00 https://theracryf.com/post_type_resource/2021-placing-form-of-proxy/ 2024-10-22T10:48:57+00:00 https://theracryf.com/post_type_resource/admission-document/ 2024-10-22T10:49:14+00:00 https://theracryf.com/post_type_resource/articles-of-association/ 2024-10-22T10:49:31+00:00 https://theracryf.com/post_type_resource/voting-on-agm-resolutions/ 2024-10-22T10:51:21+00:00 https://theracryf.com/post_type_resource/2022-interim-results-presentation/ 2024-10-22T10:52:02+00:00 https://theracryf.com/post_type_resource/investor-meet-company-results-and-agm-2023/ 2024-10-22T10:52:18+00:00 https://theracryf.com/post_type_resource/notice-of-general-meeting/ 2024-10-22T11:15:55+00:00 https://theracryf.com/post_type_resource/voting-on-gm-resolutions/ 2024-10-22T11:16:48+00:00 https://theracryf.com/post_type_resource/capital-access-group-analyst-research/ 2024-10-22T11:18:23+00:00 https://theracryf.com/post_type_resource/theracryf-plc-full-year-results/ 2024-10-22T11:18:45+00:00 https://theracryf.com/post_type_resource/theracryf-research-and-development-day/ 2024-10-22T11:19:43+00:00 https://theracryf.com/post_type_resource/notice-of-agm-and-proxy-form/ 2024-10-22T11:20:07+00:00 https://theracryf.com/post_type_resource/corporate-presentation-3/ 2024-10-22T11:20:55+00:00 https://theracryf.com/post_type_resource/notice-of-agm/ 2024-10-22T11:21:15+00:00 https://theracryf.com/post_type_resource/notice-of-agm-2/ 2024-10-22T11:21:38+00:00 https://theracryf.com/post_type_resource/notice-of-agm-3/ 2024-10-22T11:21:59+00:00 https://theracryf.com/post_type_resource/voting-on-agm-resolutions-2/ 2024-10-22T11:22:21+00:00 https://theracryf.com/post_type_resource/voting-on-agm-resolutions-3/ 2024-10-22T11:22:46+00:00 https://theracryf.com/post_type_resource/voting-on-agm-resolutions-4/ 2024-10-22T11:23:54+00:00 https://theracryf.com/post_type_resource/multiple-antitumor-molecular-mechanisms-are-activated-by-a-fully-synthetic-and-stabilized-pharmaceutical-product-delivering-the-active-compound-sulforaphane-sfx-01-in-preclinical-model-of-human-glio/ 2024-10-22T11:24:28+00:00 https://theracryf.com/post_type_resource/final-results-of-the-stem-trial-sfx-01-in-the-treatment-and-evaluation-of-er-her2-metastatic-breast-cancer-mbc-annals-of-oncology-1-october-2019/ 2024-10-22T11:26:06+00:00 https://theracryf.com/post_type_resource/sfx-01-in-the-treatment-of-rhabdomyosarcoma-preclinical-results-in-cellular-models/ 2024-10-22T11:26:51+00:00 https://theracryf.com/post_type_resource/therapeutic-targeting-of-the-nrf2-and-keap1-partnership-in-chronic-diseases-nature-reviews-drug-discovery-5-february-2019/ 2024-10-22T11:27:26+00:00 https://theracryf.com/post_type_resource/effect-of-sfx-01-on-proliferation-of-human-glioblastoma-cell-lines-biorxiv-16-september-2021/ 2024-10-22T11:28:07+00:00 https://theracryf.com/post_type_resource/investor-meet-company-proactive-investor-event-presentation/ 2024-10-22T11:28:31+00:00 https://theracryf.com/post_type_resource/corporate-presentation/ 2024-10-22T11:28:51+00:00 https://theracryf.com/post_type_resource/sulforaphane-treatment-of-autism-spectrum-disorder-asd-pnas-28-october-2014/ 2024-10-22T11:29:09+00:00 https://theracryf.com/post_type_resource/can-activation-of-nrf2-be-a-strategy-against-covid-19-trends-in-pharmacological-sciences-september-2020/ 2024-10-22T11:29:34+00:00 https://theracryf.com/post_type_resource/the-novel-atypical-dopamine-transport-inhibitor-ct-005404-has-pro-motivational-effects-in-neurochemical-and-inflammatory-models-of-effort-based-dysfunctions-related-to-psychopathology/ 2024-10-22T12:58:28+00:00 https://theracryf.com/post_type_resource/translational-evaluation-of-novel-selective-orexin-1-receptor-antagonist-jnj-61393215-in-an-experimental-model-for-panic-in-rodents-and-humans-translational-psychiatry-7-september-2020/ 2024-10-22T13:03:23+00:00 https://theracryf.com/post_type_resource/corporate-presentation-2/ 2024-10-22T13:06:19+00:00 https://theracryf.com/post_type_resource/targeting-stat3-signaling-using-stabilised-sulforaphane-sfx-01-inhibits-endocrine-resistant-stem-like-cells-in-er-positive-breast-cancer-nature-oncogene-20-may-2020/ 2024-10-22T14:12:38+00:00 https://theracryf.com/post_type_resource/agm-presentation-harnessing-the-power-of-sulforaphane/ 2024-10-22T15:41:53+00:00 https://theracryf.com/post_type_resource/corporate-presentation-harnessing-the-power-of-sulforaphane/ 2024-10-22T15:42:22+00:00 https://theracryf.com/post_type_resource/tuner-pope-investments-research/ 2025-02-19T16:27:14+00:00 https://theracryf.com/post_type_resource/capital-access-research/ 2025-02-19T16:28:03+00:00 https://theracryf.com/post_type_resource/cavendish-research/ 2025-02-19T16:37:00+00:00 https://theracryf.com/post_type_resource/notice-of-general-meeting-and-form-of-proxy/ 2025-02-20T15:32:20+00:00 https://theracryf.com/post_type_resource/voting-on-gm-resolution/ 2025-03-07T14:04:11+00:00 https://theracryf.com/post_type_resource/cavendish-research-cdmo-cro-selection/ 2025-05-14T14:23:36+00:00 https://theracryf.com/post_type_resource/capital-access-group-research-pharmaron-contract/ 2025-05-14T14:25:00+00:00 https://theracryf.com/post_type_resource/turner-pope-investments-research-note-on-full-year-results/ 2025-06-05T14:50:56+00:00 https://theracryf.com/post_type_resource/capital-access-group-research-note-on-full-year-results/ 2025-06-05T14:51:53+00:00 https://theracryf.com/post_type_resource/theracryf-plc-full-year-results-june-2025/ 2025-06-05T15:00:09+00:00 https://theracryf.com/post_type_resource/cavendish-research-note-on-full-year-results/ 2025-06-05T15:42:00+00:00 https://theracryf.com/post_type_resource/notice-of-agm-2025/ 2025-06-16T16:08:06+00:00 https://theracryf.com/post_type_resource/investor-presenation/ 2025-07-08T15:31:56+00:00 https://theracryf.com/post_type_resource/corporate-presenation/ 2025-07-08T15:32:39+00:00 https://theracryf.com/post_type_resource/voting-on-agm-resolutions-5/ 2025-07-10T10:09:49+00:00 https://theracryf.com/post_type_resource/theracryf-presentation-post-agm-july-2025/ 2025-07-10T10:11:53+00:00 https://theracryf.com/post_type_resource/theracryf-ltip-rules-2025-2/ 2025-07-15T12:10:45+00:00 https://theracryf.com/post_type_resource/theracryf-presentation-developing-innovative-therapeutics-in-brain-disorders/ 2025-11-19T15:50:59+00:00 https://theracryf.com/post_type_resource/theracryf-plc-half-year-results-to-30-september-2025/ 2025-12-04T12:10:21+00:00 https://theracryf.com/post_type_resource/capital-access-group-research-note-on-half-year-results/ 2025-12-17T17:37:53+00:00 https://theracryf.com/post_type_resource/turner-pope-investments-research-note-on-half-year-results/ 2025-12-17T17:39:27+00:00 https://theracryf.com/post_type_resource/dat-asset-potential-value-highlighted/ 2026-01-27T14:42:55+00:00 https://theracryf.com/post_type_resource/capital-access-ox-1-10kg-toxicology-study-quantity-achieved/ 2026-01-27T15:17:52+00:00 https://theracryf.com/post_type_resource/the-sulforaphane-promise/ 2026-02-27T11:01:00+00:00 https://theracryf.com/post_type_resource/capital-access-group-ox-1-imminent-start-of-final-toxicology-study/ 2026-03-23T16:38:46+00:00 https://theracryf.com/post_type_resource/capital-access-group-orexin-ma-demonstrates-industry-appetite/ 2026-04-13T17:02:38+00:00 https://theracryf.com/post_type_resource/capital-access-group-ox-1-dat-programmes-indicative-proposal/ 2026-04-14T09:17:57+00:00 https://theracryf.com/post_type_resource/turner-pope-investments-indicative-proposal-for-ox-1-dat-programmes/ 2026-04-14T10:03:09+00:00 https://theracryf.com/post_type_resource/capital-access-group-patent-protection-potentially-extending-to-2046/ 2026-04-21T21:12:49+00:00 https://theracryf.com/post_type_resource/turner-pope-investments-theracryf-plc-research-note/ 2026-04-21T21:32:04+00:00 https://theracryf.com/post_type_resource/turner-pope-investments-top-line-toxicology-data/ 2026-05-14T16:21:36+00:00 https://theracryf.com/post_type_resource/notice-of-gm-and-form-of-proxy/ 2026-08-20T16:19:15+00:00 https://theracryf.com/post_type_resource/theracryf-plc-amended-articles-of-association-draft/ 2026-08-20T16:22:12+00:00 https://theracryf.com/post_type_resource/capital-access-group-theracryf-1-1m-raise-progressing-ox-1-to-clinical-trial/ 2026-08-21T09:17:16+00:00 https://theracryf.com/post_type_resource/theracryf-articles-of-association-amended/ 2026-09-09T08:57:55+00:00 https://theracryf.com/post_type_resource/theracryf-investor-presentation-results-to-31-march-2026/ 2026-09-28T16:01:11+00:00 https://theracryf.com/post_type_resource/theracryf-plc-rules-of-the-2026-ltip-draft/ 2026-10-01T09:04:24+00:00 https://theracryf.com/post_type_resource/theracryf-plc-notice-of-agm-and-proxy-form/ 2026-10-01T09:05:54+00:00